Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Percentage of low risk of bias studies per treatment arm in the meta-analysis on exacerbation rate [13, 15, 19, 33–42]
| Treatment | Percentage |
|---|---|
| Benralizumab | 60% (3/5) |
| Lebrikizumab | 50% (1/2) |
| Dupilumab | 0% (0/1) |
| Mepolizumab | 50% (1/2) |
| Tralokinumab | 100% (1/1) |
| Reslizumab | 100% (1/1) |
| Tezepelumab | 100% (1/1) |
Table outlining the risk of bias for different studies included in the meta-analysis, all agents had at least 50% of low-risk studies included, except dupilumab
